Oral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culprits

References

• CompstonAColesAMultiple sclerosisLancet200837296481502151718970977
   PubMed Web of Science ®Google Scholar
• ThöneJGoldRLaquinimod: a promising oral medication for the treatment of relapsing-remitting multiple sclerosisExpert Opin Drug Metab Toxicol20117336537021306281
   PubMed Web of Science ®Google Scholar
• BrückWZamvillSSLaquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosisExpert Rev Clin Pharmacol20125324525622697588
   PubMed Web of Science ®Google Scholar
• RunströmALeandersonTOhlssonLAxelssonBInhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta ko and wild type miceJ Neuroimmunol20061731–2697816472873
   PubMed Web of Science ®Google Scholar
• ThöneJEllrichmannGSeubertSModulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factorAm J Pathol2012180126727422152994
   PubMed Web of Science ®Google Scholar
• BrückWPförtnerRPhamTReduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelinationActa Neuropathol2012124341142422766690
   PubMed Web of Science ®Google Scholar
• AharoniRSaadaREilamRHayardenyLSelaMArnonROral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitisJ Neuroimmunol20122511–2142422749337
   PubMed Web of Science ®Google Scholar
• MishraMKWangJSilvaCMackMYongVWKinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimodAm J Pathol2012181264265122749771
   PubMed Web of Science ®Google Scholar
• PolmanCBarkhofFSandberg-WollheimMTreatment with laquinimod reduces development of active MRI lesions in relapsing MSNeurology200564698799115781813
   PubMed Web of Science ®Google Scholar
• ComiGPulizziARovarisMEffect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLancet200837196302085209218572078
   PubMed Web of Science ®Google Scholar
• ComiGAbramskyAArbizuTOral laquinimod in patients with relapsing–remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled studyMult Scler201016111360136620834039
   PubMed Web of Science ®Google Scholar
• ComiGJefferyDKapposLPlacebo-controlled trial of oral laquinimod for multiple sclerosisN Engl J Med2012366111000100922417253
   PubMed Web of Science ®Google Scholar
• CMSC INForMS: Results of phase III BRAVO trial Reinforce Unique profile of Laquinimod for MS [webpage on the Internet]HackensackConsortium of the Multiple Sclerosis Centers2011 Available from: http://bit.Ly/oAuZD6Accessed February 12, 2012
   Google Scholar
• ScottLJFingolimod: a review of its use in the management of relapsing-remitting multiple sclerosisCNS Drugs201125867369821790210
   PubMed Web of Science ®Google Scholar
• KapposLAntelJComiGOral fingolimod (FTY720) for relapsing multiple sclerosisN Engl J Med2006355111124114016971719
   PubMed Web of Science ®Google Scholar
• ComiGO’ConnorPMontalbanXPhase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year resultsMult Scler201016219720720028707
   PubMed Web of Science ®Google Scholar
• KapposLRadueEWO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740120089952
   PubMed Web of Science ®Google Scholar
• DevonshireVHavrdovaERadueE WRelapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS studyLancet Neurol201211542042822494956
   PubMed Web of Science ®Google Scholar
• CohenJABarkhofFComiGOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med2010362540241520089954
   PubMed Web of Science ®Google Scholar
• KhatriBBarkhofFComiGComparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS studyLancet Neurol201110652052921571593
   PubMed Web of Science ®Google Scholar
• PoulsenRRMcClaskeyCMRivkeesSAWendlerCCThe Sphingosine-1-phospate receptor 1 mediates S1P action during cardiac developmentBMC Dev Biol2011113721668976
   PubMed Web of Science ®Google Scholar
• MontalbanXComiGO’ConnorPOral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II studyMult Scler201117111341135021727148
   PubMed Web of Science ®Google Scholar
• ClaussenMCKornTImmune mechanisms of new therapeutic strategies in MS: teriflunomideClin Immunol20121421495621367665
   PubMed Web of Science ®Google Scholar
• GoldRWolinskyJSPathophysiology of multiple sclerosis and the place of teriflunomideActa Neurol Scand20111242758420880295
   PubMed Web of Science ®Google Scholar
• O’ConnorP WLiDFreedmanMSTeriflunomide Multiple Sclerosis Trial GroupUniversity of British Columbia MS/MRI Research GroupA Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapsesNeurology200666689490016567708
   PubMed Web of Science ®Google Scholar
• FreedmanMSWolinskyJSWamil B, et al; Teriflunomide Multiple Sclerosis Trial Group and the MRI Analysis Center. Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trialNeurology201278231877188522622860
   PubMed Web of Science ®Google Scholar
• FreedmanMSWolinskyJSWamilBOral teriflunomide plus glatiramer acetate in relapsing multiple sclerosis [abstract P17]Int J MS Care2011139
   Google Scholar
• O’ConnorPWolinskyJSConfavreuxCRandomized trial of oral teriflunomide for relapsing multiple sclerosisN Engl J Med2011365141293130321991951
   PubMed Web of Science ®Google Scholar
• Genzyme Reports Top-line Results for TENERE Study of Oral Teriflunomide in Relapsing Multiple Sclerosis [webpage on the Internet]CambridgeBusiness Wire2011 Available from: http://www.businesswire.com/news/home/20111219006550/en/Genzyme-Reports-Top-line-Results-TENERE-Study-OralAccessed December 4, 2012
   Google Scholar
• StuveOBenamorMBenzerdjebHKieseierBPregnancy Outcomes from the teriflunomide clinical development program: retrospective analysis of a global pharmacovigilance database [abstract]Neurology201278Meeting Abstracts 1P06.190
   Google Scholar
• LeistTPWeissertRCladribine: mode of action and implications for treatment of multiple sclerosisClin Neuropharmacol2011341283521242742
   PubMed Web of Science ®Google Scholar
• BeutlerESipeJCRomineJSKoziolJAMcMillanRZyroffJThe treatment of chronic progressive multiple sclerosis with cladribineProc Natl Acad Sci USA1996934171617208643695
   PubMed Web of Science ®Google Scholar
• SipeJCRomineJSKoziolJAMcMillanRZyroffJBeutlerECladribine in treatment of chronic progressive multiple sclerosisLancet19943489149137912347
   PubMed Web of Science ®Google Scholar
• GiovannoniGComiGCookSCLARITY Study GroupA placebo-controlled trial of oral cladribine for relapsing multiple sclerosisN Engl J Med2010362541642620089960
   PubMed Web of Science ®Google Scholar
• GiovannoniGCookSRammohanKCLARITY study groupSustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysisLancet Neurol201110432933721397565
   PubMed Web of Science ®Google Scholar
• HartungHPAktasOKieseierBGiancarlo ComiGCDevelopment of oral cladribine for the treatment of multiple sclerosisJ Neurol2010257216317019921304
   PubMed Web of Science ®Google Scholar
• SipeJCCladribine for multiple sclerosis: review and current statusExpert Rev Neurother20055672172716274330
   PubMedGoogle Scholar
• US Food and Drug Administration [homepage on the Internet]Silver SpringFDA2012 Available from: http://www.fda.govAccessed December 4, 2012
   Google Scholar
• European Medicines Agency [homepage on the Internet]LondonEMA2011 Available from: http://www.ema.europa.eu/emaAccessed December 4, 2012
   Google Scholar
• multiple Sclerosis Resource Center [homepage on the Internet]ColchesterMSRC2012 Available from: http://www.msrc.co.ukAccessed December 4, 2012
   Google Scholar
• LinkerRALeeDHRyanSFumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathwayBrain2011134Pt 367869221354971
   PubMed Web of Science ®Google Scholar
• PapadopoulouAD’SouzaMKapposLYaldizliODimethyl fumarate for multiple sclerosisExpert Opin Investig Drugs2010191216031612
   PubMed Web of Science ®Google Scholar
• SchimrigkSBruneNHellwigKOral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot studyEur J Neurol200613660461016796584
   PubMed Web of Science ®Google Scholar
• GoldRKapposLArnoldDLDEFINE Study InvestigatorsPlacebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisN Engl J Med2012367121098110722992073
   PubMed Web of Science ®Google Scholar
• FoxRJMillerDHPhillipsJTCONFIRM Study InvestigatorsPlacebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisN Engl J Med2012367121087109722992072
   PubMed Web of Science ®Google Scholar